Detect, identify and decide
Delve Decide is the proprietary platform that powers Delve Bio’s metagenomic testing, built to deliver unrivaled accuracy, reliability and speed.
Optimized for actionability
Delve Decide’s bioinformatic pipeline, curated pathogen database and clinical interpretation software are robust, fast and reliable. Delve Decide rapidly analyzes DNA and RNA, sorting millions of sequences to identify the genetic signatures of potential pathogens using a broad, curated database, delivering comprehensive microbial analysis impossible through conventional hypothesis-guided testing.
World-class genomic sequencing
Delve Bio has partnered with Broad Clinical Labs, a CLIA-licensed and CAP-accredited, wholly owned subsidiary of the Broad Institute of MIT and Harvard for sample processing and sequencing. Broad Clinical Labs brings more than three decades of experience at the cutting edge of genomic research and application to all Delve’s customers.
Generate optimized sequence data
Specialized sample processing includes enrichment for RNA viruses and DNA viruses, bacterial, fungi and parasites. The process is optimized for sensitivity, specificity, and contamination-free sequence data
Detect potential pathogen sequences
Preprocessing filtering and human host background subtraction quickly focuses on potential pathogens.
Identify likely pathogens
A custom-curated database covering more than 68,000 known and emerging pathogens, followed by additional filtering and taxonomic classification identifies pathogens present.
Automated identification
Automated bioinformatics identifies virus RNA and DNA, as well as bacterium, fungus and parasite DNA.
Decide next steps
Automated results reporting, including a heat map or read counts and a graphical interface of aligned counts, interpreted by our expert clinicians provides actionable information to guide clinical next steps.